An observational study in Ovarian, Aging and Healthspan Improvement, sponsored by Sheba Medical Center. Not yet recruiting at 1 site in Israel. Open to female participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Sheba Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.
Background and Purpose:
The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.
Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.
Part 2: Prospective OASIS Cohort
This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:
Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.
Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.
Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.
Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.
Sheba Medical Center is the lead sponsor of 680 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 3 (PRISM substudy) specific criteria:
Exclusion Criteria:
Part 3 (PRISM substudy) specific criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis.
300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings.
Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes.
Reproductive hormone concentrations
The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples.
Time frame: Baseline, 12 months, 24 months
Antral Follicle Count (AFC)
The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound.
Time frame: Baseline, 12 months, 24 months
Total ovarian volume
Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries.
Time frame: Baseline, 12 months, 24 months
Number of participants with abnormal ovarian or adnexal ultrasound findings
The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded.
Time frame: Baseline, 12 months, 24 months
Circulating ovarian-associated molecular signature
Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function.
Time frame: Baseline, 12 months
Montreal Cognitive Assessment (MoCA) score
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.
Time frame: Baseline, 12 months
Apnea-Hypopnea Index (AHI)
Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep.
Time frame: Baseline, 12 months
Glycated hemoglobin (HbA1c)
Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples.
Time frame: Baseline, 12 months
DXA-derived body composition
Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg).
Time frame: Baseline, 12 months
Bone mineral density (BMD)
Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm².
Time frame: Baseline, 12 months
Handgrip strength
Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg).
Time frame: Baseline, 12 months
Pulse wave velocity (PWV)
Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s).
Time frame: Baseline, 12 months
Within-woman changes in reproductive endocrine measures
Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants.
Time frame: Up to four sampling time points during the first month of the study
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Nov 2029, 35 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.